Predict your next investment

Cepheid company logo
Corporation
HEALTHCARE | Medical Devices & Equipment / Imaging & Diagnostic Equipment
cepheid.com

See what CB Insights has to offer

Founded Year

1996

Stage

Grant | Alive

Total Raised

$60.7M

Valuation

$0000 

Last Raised

$28M | 2 mos ago

Revenue

$0000 

About Cepheid

Cepheid is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial, and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification, and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. Cepheid previously traded under the ticker NASDAQ: CPHD.

Cepheid Headquarter Location

904 Caribbean Drive

Sunnyvale, California, 94089,

United States

408-541-4191

Latest Cepheid News

FDA grants EUA to Cepheid’s rapid Covid-19/Flu/RSV diagnostic test

Sep 15, 2021

15 Sep 2021 (Last Updated September 15th, 2021 09:52) Xpert Xpress CoV-2/Flu/RSV plus works on Cepheid’s GeneXpert Systems and offers results in nearly 36 minutes. Share Article Xpert Xpress CoV-2/Flu/RSV plus can detect viruses causing Covid-19, Flu A/B and RSV infections from a single patient sample. The US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to Cepheid’s rapid molecular diagnostic test, Xpert Xpress CoV-2/Flu/RSV plus. The test is indicated for qualitative identification of the viruses that cause Covid-19, Flu A, Flu B and respiratory syncytial virus (RSV) infections in a single patient sample. The latest plus version of the test offers a third gene target for the SARS-CoV-2 virus in order to boost the potential for identifying any viral mutations in the future. Several variants of the SARS-CoV-2 virus have been detected across the globe during the pandemic. As viruses frequently change through mutation, new viral variants are anticipated to arise over time. Cepheid noted that including a third gene target to the plus version of the CoV-2/Flu/RSV test offers extensive coverage to alleviate the potential impact of viral genetic drift in the future. Xpert Xpress CoV-2/Flu/RSV plus can be used on any of Cepheid’s GeneXpert Systems, of which there are more than 35,000 available globally, and offers results in nearly 36 minutes. Cepheid chief medical and technology officer Dr David Persing said: “This respiratory season, healthcare providers may encounter a range of viral infections with symptoms that overlap with Covid-19, including Flu A, Flu B and respiratory syncytial virus. “Having a fast and accurate test that is designed to detect current and future variants of the viruses that cause Covid-19 and influenza will become increasingly important. “The ability to collect one sample and run a single, highly-sensitive multiplexed test that detects and differentiates all four viruses will provide actionable results to inform better front-line decisions within our healthcare systems.” The company noted that the new test is authorised only to qualitatively identify and distinguish nucleic acid from SARS-CoV-2, influenza A virus, influenza B virus and RSV, simultaneously, and not any other viruses or pathogens. Cepheid anticipates commencing shipping of Xpert Xpress CoV-2/Flu/RSV plus to users in the US in the coming weeks.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cepheid

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cepheid is included in 5 Expert Collections, including Genomics.

G

Genomics

823 items

Companies involved in the capture, sequencing, and/or analysis of genetic data

I

Infectious Disease

2,226 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

O

Omics

1,025 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

M

Medical Devices

3,578 items

https://www.amdm.org/members.html

H

Health & Wellness Assessment

697 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

Cepheid Patents

Cepheid has filed 138 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • DNA
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/25/2019

9/7/2021

Graphical user interface elements, Graphical user interfaces, Graphical control elements, Graphical user interface testing, Computing input devices

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/25/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/7/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Graphical user interface elements, Graphical user interfaces, Graphical control elements, Graphical user interface testing, Computing input devices

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Cepheid Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cepheid Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.